TABLE 4.
Total antibody and antibody subtype levels at days 7 and 21 after intraperitoneal Ty21a-pBR322 administration to mice treated with clarithromycin, doxycycline, ampicillin, or NS
| Day postvaccination | Antibody subtype | Serum dilution | Antibody level (A492)
|
|||||
|---|---|---|---|---|---|---|---|---|
| Mean for group treated
with:
|
SEM (pooled) | Critical value | ||||||
| Clarithromycin (n = 10) | Doxycycline (n = 10) | Ampicillin (n = 10) | NS (n = 10) | |||||
| 7 | Total | 1:25 | 0.096 | 0.100 | 0.132a | 0.069a | 0.110 | 0.043 |
| IgM | 1:25 | 0.226b | 0.232c | 0.234d | 0.122bcd | 0.024 | 0.093 | |
| IgG1 | 1:25 | 0.012 | 0.013 | 0.011 | 0.013 | 0.001 | 0.004 | |
| IgG2a | 1:25 | 0.010 | 0.010 | 0.020 | 0.010 | 0.004 | 0.016 | |
| 21 | Total | 1:25 | 0.681 | 0.523e | 0.973ef | 0.302f | 0.101 | 0.386 |
| IgM | 1:25 | 0.482g | 0.524h | 0.472i | 0.158ghi | 0.043 | 0.162 | |
| IgG1 | 1:25 | 0.017 | 0.015 | 0.012 | 0.012 | 0.002 | 0.007 | |
| IgG2a | 1:25 | 0.019 | 0.017 | 0.019 | 0.017 | 0.004 | 0.016 | |
a–i The difference is statistically significant compared to the mean with the same superscript.